Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rein Therapeutics ( (RNTX) ) has issued an announcement.
On December 11, 2025, Rein Therapeutics, Inc. decided to terminate its Pre-Paid Advance Agreement and Standby Equity Purchase Agreement with YA II PN, Ltd., a Cayman Islands exempt limited partnership. The company had previously received $3 million in advances under the PPA, with the last advance taken on October 23, 2025, but did not sell any common stock under the SEPA. The termination of these agreements did not result in any penalties or fees for the company.
The most recent analyst rating on (RNTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Rein Therapeutics stock, see the RNTX Stock Forecast page.
Spark’s Take on RNTX Stock
According to Spark, TipRanks’ AI Analyst, RNTX is a Underperform.
Rein Therapeutics is experiencing severe financial difficulties, with persistent negative net income and cash flows. The technical analysis suggests bearish momentum with potential near-term volatility. The negative P/E ratio and lack of dividends further highlight the company’s weak financial position. The overall outlook for the stock is challenging, with significant risks outweighing potential rewards.
To see Spark’s full report on RNTX stock, click here.
More about Rein Therapeutics
Average Trading Volume: 958,804
Technical Sentiment Signal: Sell
Current Market Cap: $38.12M
Learn more about RNTX stock on TipRanks’ Stock Analysis page.